SA
HCM logo
HUTCHMED (China) Limited(HCM)
Closing price · checked 8:25 PM ETAbout this dataData status
$13.22▼-0.23 (-1.71%)
Extended:$13.22+0.00 (+0.00%)· 8:25 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

HUTCHMED (China) Limited (HCM)

R&D to Revenue

28.21%

Fiscal year · Period ending:

HCM logo

HCM R&D to Revenue

Latest reported28.21%
HCM FY R&D/Revenue (5.41% → 28.21%)
Powered by
High-resolution chart · PNG

What is r&d to revenue?

R&D spending as percentage of revenue.

HCM r&d to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it, in percentage points.

HUTCHMED (China) Limited R&D to Revenue — Annual fiscal periods
Period endingR&D to RevenueChange
28.212%−5.45 pts
33.6574%−2.38 pts
36.0383%−26.72 pts
62.7536%+4.50 pts
58.2507%+9.46 pts
48.792%+3.92 pts
44.8748%+8.06 pts
36.8135%+15.80 pts
21.0093%−9.94 pts
30.9473%+4.37 pts
26.5809%−9.88 pts
36.4567%−14.52 pts
50.9789%+47.96 pts
3.0165%−1.35 pts
4.3674%−0.39 pts
4.762%+1.29 pts
3.4742%−6.65 pts
10.1269%+1.46 pts
8.6679%+3.17 pts
5.4967%+0.09 pts
5.4071%—

Frequently asked questions: HCM r&d to revenue

What is HUTCHMED (China) Limited (HCM)'s current r&d to revenue?

HUTCHMED (China) Limited (HCM)'s latest reported r&d to revenue (Fiscal year) is 28.21% as of Dec 31, 2025. R&D spending as percentage of revenue.

How much historical r&d to revenue data is available for HCM?

Stock Alarm Pro provides 21 dated annual fiscal periods observations for HUTCHMED (China) Limited (HCM)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare HCM's r&d to revenue to peers or set an alert?

You can open HCM's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on HCM delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.